French company Nicox S.A. (Euronext: COX) has announced that affiliate companies of itself and Sequenom Inc (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement that grants North American promotional rights to Nicox for the Sequenom Laboratories “RetnaGen AMD” test designed for the evaluation of a patient’s risk of AMD disease progression. The company announced that the test will be promoted by the same Nicox U.S. sales force which recently launched an advanced diagnostic panel for the early detection of Sjogren’s Syndrome, a chronic autoimmune disease. Marketing of the AMD test in the US is expected in the first half of 2014.